Compare Stitch Fix Inc (SFIX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stitch Fix Inc vs Sanofi SA — how do they compare? Stitch Fix Inc trades at $3.63 (market cap $497.68M), while Sanofi SA trades at $43.47 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 209.6× Stitch Fix Inc's market cap, and Sanofi SA pays a 5.55% dividend while Stitch Fix Inc pays none. Which is the better fit depends on your goals.
| SFIX | SNY | |
|---|---|---|
Market Cap | $497.68M | $104.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $5.83 | $52.34 |
52-Week Low | $3.06 | $41.33 |
Enterprise Value | $385.40M | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stitch Fix (SFIX) trades at $3.97, down 5.48% today, as the online personal styling service shows mixed signals. While revenue has stabilized around $1.3B annually and losses are narrowing significantly, the company remains unprofitable with a -1.43% net margin. Technical indicators show a bullish trend with strong momentum signals, though oscillators remain neutral. Recent news highlights AI-driven personalization initiatives and active client growth as potential turnaround catalysts.
The stock presents a speculative recovery opportunity with improving fundamentals but carries execution risks. Analyst consensus is cautious with a $4.75 price target (20% upside) but only 27% buy ratings. Key risks include consumer spending pressure and the challenge of achieving sustainable profitability in the competitive retail sector.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
